Based on their results, they propose utilization of IDH inhibitor and ICB in the clinical practices to treat IDH‐mutant glioma [79], which indeed would be particularly valuable for the PMMRDIA group, which is otherwise resistant to TMZ. This evidence concerns the gene IDH2 and glioma.